RWE and Patient-Centered Outcomes
Widespread availability of real-world data has enabled the generation of evidence and insights that benefit patients, providers, plans, and industry. When that evidence reflects patient outcomes, it provides an invaluable perspective on the consumer experience. Explore our real-world evidence (RWE) analyses and guidance to support your strategic decisions.
RWE Considerations Throughout Product Development Cycle
Drug manufacturers can use real-world evidence (RWE) before and after approval to advance product development and adoption.
Video: The Future of Patient-Centric Value
Avalere experts Amanda Napoles and Shelby Harrington share recommendations for shifting to patient-centered value during our 2023 Outlook webinar.
Coding, Billing, and Reimbursement Barriers to Obesity Care
Assessing barriers that impact patient access to obesity care and educating stakeholders on how to mitigate them can advance solutions toward improving care.
Patient- and Caregiver-Centered Value in Rare Disease Treatment
Traditional health technology assessments fall short in accounting for how therapy addresses the total burden of illness experienced by affected individuals.
Video: Patient-Centered Value Frameworks
Avalere experts will discuss patient-centric value frameworks, their utility to different stakeholders, and how they can drive the transformation to a patient-centered, equitable health system at the AMCP Nexus 2022 conference.
Patient–Provider Collaboration: Shared Decision Making in Cancer Care
In the latest installment of Avalere’s ongoing insight series about shared decision making, Michelle Bruno, Associate Principal in Avalere’s Center for Healthcare Transformation, describes the role it can play in cancer care.
Avalere Expands Data and Analytics Focus with New Addition
Avalere Health welcomes Mandar Karhade, who supports healthcare outcomes research and data commercialization through innovation and advanced technology.
Shared Decision Making: An Insight Series on Clinician-Patient Collaboration Improving Engagement & Outcomes
A new series explores how shared decision-making can be applied in multiple therapeutic areas to reach patient, clinician, and other stakeholders’ goals.
Medicare Beneficiary Care Differences by Practice Ownership
Avalere released a white paper analyzing spending and utilization among Medicare beneficiaries receiving care from independent physician practices and hospital-owned physician practices in Ohio.
Alex Du Joins Avalere Health’s Market Access Practice
Avalere Health welcomes Alex (Shuang) Du as an associate principal to its Market Access practice. He will support a variety of Avalere’s clients in navigating the evolving healthcare landscape.
Majority of API in US-Consumed Medicines Is Produced in the US
Analysis of the most recent available trade data finds that 53% of API, in dollars, used in domestically consumed medicines came from the US in 2020.
Treating Depression Reduces Medicare Costs; Provider Challenges Remain
A recent Avalere analysis of Medicare Fee-for-Service (FFS) data illustrates that treating major depressive disorder (MDD) in Medicare-eligible beneficiaries results in a 4% reduction in total cost compared to untreated patients, highlighting the importance of incentivizing adequate provider supply and payment in the geriatric psychiatry market.
Admissions From EDs Increased for FFS Beneficiaries in 2020
In 2020, the total number of emergency department (ED) visits for Medicare fee-for-service (FFS) beneficiaries declined, but patients presenting with non-emergency care sensitive conditions were more likely to be admitted than in 2019.
Utilization Management Trends in the Commercial Market, 2014–2020
A new Avalere analysis examines the prevalence of utilization management (UM) in the commercial market from 2014 to 2020, focusing on drugs treating cancer, autoimmune diseases, and a range of other chronic conditions.
Digital Health Advances Create Opportunities for Access and Engagement
Digital health solutions continue to advance the way healthcare is delivered. Through research and development as well as stakeholder partnerships, life science companies can leverage digital health technologies to optimize access along the patient care journey.
Rare and Orphan Disease Therapies Require New Distribution Strategies
Manufacturers currently in the developmental phase for drug assets targeting rare or orphan diseases should assess the commercialization implications when bringing novel therapies to market and how they may differ from the standard pharmaceutical supply chain and economics.
Webinar: Looking Ahead: The Evolving Oncology Landscape
Avalere experts examined the changing oncology landscape amid the COVID-19 pandemic.
AI in Healthcare: Raise the Evidence Bar Now or Be Forced to Later
In 2012, experts predicted that artificial Intelligence (AI) would eventually replace as much as 80% of current clinical practice by physicians. While AI has certainly expanded in healthcare—especially during the COVID-19 pandemic—the last few years have included some eventful setbacks in the use of AI across several sectors of the economy, including healthcare.
Podcast: Infusing the Patient Perspective into Value Assessment, Part III
Tune into another episode of Avalere Health Essential Voice in our Start Your Day with Avalere series. In the final segment of our series on infusing the patient perspective into value assessment, our experts discuss the Patient Perspective Value Framework (PPVF) developed by Avalere Health and FasterCures, which employs a form of multi-criteria decision analysis to capture value according to patients.
Video: COVID-19 and Oncology Care
Tune into another episode in the Avalere Health Essential Voice series focused on disease education. In this segment, experts from Community Oncology Alliance (COA) and Texas Oncology join us to discuss the impact of COVID-19 on oncology care from a provider and patient perspective.